Search results for "INHIBITOR"

showing 10 items of 3742 documents

The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections

2020

This review updates current knowledge regarding the risk of viral infections, including COVID-19, in patients treated with cyclosporine. We also shortly refer to bacterial infections and parasitic infestations in patients treated with cyclosporin. Cyclosporine is an immunosuppressive drug, which is widely used in medicine, including in the treatment of autoimmune skin diseases in dermatology, rheumatology, ophthalmology and nephrology, and in organ transplantation. A usual concern associated with immunosuppressive treatment is the potential risk of infections. Interestingly, several data indicate a relatively low risk of infections, especially viral infections, in patients receiving cyclosp…

0301 basic medicinemedicine.medical_specialtyvirusesmedicine.medical_treatmentHepatitis C viruscoronavirusReviewBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyVirusOrgan transplantation030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRotavirusmedicinecyclosporineinfectionstacrolimuslcsh:QH301-705.5Coronavirushuman papilloma virus infectionGeneral Immunology and MicrobiologyHepatitis Cmedicine.diseasecalcineurin inhibitorshuman herpesvirusVirologyTacrolimusAIDShepatitis flu030104 developmental biologyImmunosuppressive druglcsh:Biology (General)cyclophilinGeneral Agricultural and Biological SciencesBiology
researchProduct

Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy

2018

Research on the antiepileptic effects of (endo-)cannabinoids has remarkably progressed in the years following the discovery of fundamental role of the endocannabinoid (eCB) system in controlling neural excitability. Moreover, an increasing number of well-documented cases of epilepsy patients exhibiting multi-drug resistance report beneficial effects of cannabis use. Pre-clinical and clinical research has increasingly focused on the antiepileptic effectiveness of exogenous administration of cannabinoids and/or pharmacologically induced increase of eCBs such as anandamide (also known as arachidonoylethanolamide [AEA]). Concomitant research has uncovered the contribution of neuroinflammatory p…

0301 basic medicinemedicine.medical_treatmentFAAH inhibitorsPharmacologyeicosanoidslcsh:RC321-57103 medical and health scienceschemistry.chemical_compoundEpilepsyCellular and Molecular Neuroscience0302 clinical medicineFatty acid amide hydrolaseMedicineantiepileptic drugsPentylenetetrazolendocannabinoidsMolecular Biologypalmitoylethanolamidelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal ResearchPalmitoylethanolamidebusiness.industryAnandamidemedicine.diseaseEndocannabinoid system030104 developmental biologyAnticonvulsantchemistryLC-MRMSystemic administrationlipidomicsepilepsybusiness030217 neurology & neurosurgerymedicine.drugNeuroscienceFrontiers in Molecular Neuroscience
researchProduct

Lipoproteins LDL versus HDL as nanocarriers to target either cancer cells or macrophages

2020

free open access article 31 p.; International audience; In this work, we have explored natural unmodified low- and high-density lipoproteins (LDL and HDL) as selective delivery vectors in colorectal cancer therapy. We show in vitro in cultured cells and in vivo (NanoSPECT/CT) in the CT-26 mice colorectal cancer model that LDLs are mainly taken up by cancer cells, while HDLs are preferentially taken up by macrophages. We loaded LDLs with cisplatin and HDLs with the heat shock protein-70 inhibitor AC1LINNC, turning them into a pair of “Trojan horses” delivering drugs selectively to their target cells as demonstrated in vitro in human colorectal cancer cells and macrophages, and in vivo. Coupl…

0301 basic medicinemedicine.medical_treatmentcisplatinlcsh:Medicineheat shock protein inhibitorCancer immunotherapy[CHIM.THER]Chemical Sciences/Medicinal ChemistrySpectrum Analysis RamanMiceDrug Delivery Systems0302 clinical medicineCancer immunotherapyChemistryRselective cell targetingGeneral Medicine3. Good healthLipoproteins LDLOncology030220 oncology & carcinogenesisMedicinecancer therapylipids (amino acids peptides and proteins)Colorectal NeoplasmsLipoproteins HDLResearch Articlemedicine.drug[CHIM.THER] Chemical Sciences/Medicinal ChemistryLipoproteinsTherapeuticsCell Line03 medical and health sciencesImmune systemIn vivoCell Line TumormedicinevectorizationAnimalsHumansCisplatinMacrophageslcsh:RCancermedicine.diseaseColorectal cancerIn vitro030104 developmental biologyCancer cellCancer researchNanocarriers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Initiation of Vancomycin Therapy and the First Therapeutic Drug Monitoring

2021

Abstract There have been a limited number of studies in Latvia that were focused on vancomycin therapeutic drug monitoring (TDM), especially during the initiation phase of the therapy. The aim of this study was to investigate details of vancomycin therapy in its initiation phase and to analyse the results of the first therapeutic drug monitoring within a multidisciplinary hospital in Latvia. A retrospective observational study was performed in a multidisciplinary hospital in Latvia. Adult patients hospitalised in an intensive care unit and undergoing vancomycin therapy with at least one concentration measurement were included in this study. Data about patients included demographic and clini…

0301 basic medicinenarrow therapeutic rangeMultidisciplinaryGeneral interestmedicine.diagnostic_testconcentration measurementScience030106 microbiologyQantibacterial agentsPharmacologyminimum inhibitory concentrationVancomycin therapy03 medical and health sciencesMinimum inhibitory concentration0302 clinical medicineTherapeutic drug monitoringmedicine030212 general & internal medicineProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors

2021

The approval of the first HIV-1 protease inhibitors (HIV-1 PRIs) marked a fundamental step in the control of AIDS, and this class of agents still represents the mainstay therapy for this illness. Despite the undisputed benefits, the necessary lifelong treatment led to numerous severe side-effects (metabolic syndrome, hepatotoxicity, diabetes, etc.). The HIV-1 PRIs are capable of interacting with “secondary” targets (off-targets) characterized by different biological activities from that of HIV-1 protease. In this scenario, the in-silico techniques undoubtedly contributed to the design of new small molecules with well-fitting selectivity against the main target, analyzing possible undesirabl…

0301 basic medicineon/off-targetsProtein ConformationComputer sciencemedicine.medical_treatmentHIV InfectionsLigands01 natural sciencesHIV ProteaseHIV-1 proteaseCatalytic DomainDrug DiscoveryBiology (General)DRUDITSpectroscopyMolecular StructurebiologyGeneral MedicineResearch processSmall moleculeComputer Science ApplicationsMolecular Docking SimulationChemistryligand-structure basedQH301-705.5NCI databaseComputational biologyArticleCatalysisInorganic ChemistryStructure-Activity Relationshipmolecular descriptors03 medical and health sciencesHIV-1 proteasemedicineHumansComputer SimulationPhysical and Theoretical ChemistryQD1-999Molecular BiologyVirtual screeningProteaseOrganic ChemistryHIV Protease Inhibitorsmolecular dockingvirtual screening0104 chemical sciences010404 medicinal & biomolecular chemistry030104 developmental biologyDrug DesignHIV-1biology.proteinInternational Journal of Molecular Sciences
researchProduct

p27Kip1 regulates alpha-synuclein expression

2018

Alpha-synuclein (α-SYN) is the main component of anomalous protein aggregates (Lewy bodies) that play a crucial role in several neurodegenerative diseases (synucleinopathies) like Parkinson’s disease and multiple system atrophy. However, the mechanisms involved in its transcriptional regulation are poorly understood. We investigated here the role of the cyclin-dependent kinase (Cdk) inhibitor and transcriptional regulator p27Kip1 (p27) in the regulation of α-SYN expression. We observed that selective deletion of p27 by CRISPR/Cas9 technology in neural cells resulted in increased levels of α-SYN. Knock-down of the member of the same family p21Cip1 (p21) also led to increased α-SYN levels, in…

0301 basic medicinep27Kip1[SDV]Life Sciences [q-bio]03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCyclin-dependent kinaseTranscriptional regulationalpha synucleinAlpha synucleinPsychological repressionE2F4Alpha-synucleinSynucleinopathiesbiologyPromoterEnzyme inhibitorsMolecular biologyExpressió gènica3. Good healthnervous system diseases030104 developmental biologyOncologychemistryInhibidors enzimàticsnervous systemE2F4biology.proteinGene expressionTranscription Factor E2F4transcriptionp21Cip1Transcription030217 neurology & neurosurgeryResearch Paper
researchProduct

Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates

2018

A family of dipeptidyl enoates has been prepared and tested against the parasitic cysteine proteases rhodesain, cruzain and falcipain-2 related to sleeping sickness, Chagas disease and malaria, respectively. They have also been tested against human cathepsins B and L1 for selectivity. Dipeptidyl enoates resulted to be irreversible inhibitors of these enzymes. Some of the members of the family are very potent inhibitors of parasitic cysteine proteases displaying k2nd (M−1s−1) values of seven orders of magnitude. In vivo antiprotozoal testing was also performed. Inhibitors exhibited IC50 values in the micromolar range against Plasmodium falciparum, Trypanosoma brucei, Trypanosoma cruzi and ev…

0301 basic medicinesleeping sicknessClinical BiochemistryPharmaceutical Science01 natural sciencesBiochemistryCathepsin BinhibitorsDrug Discoverychemistry.chemical_classificationbiologyChemistryDipeptidesHep G2 CellsMolecular Docking SimulationCysteine EndopeptidasesBiochemistryAntiprotozoalMolecular MedicineChagas diseaseProteasesCell Survivalmedicine.drug_classPlasmodium falciparumTrypanosoma brucei bruceimalariaAntiprotozoal AgentsCysteine Proteinase InhibitorsTrypanosoma bruceicysteine proteasesInhibitory Concentration 50Structure-Activity Relationship03 medical and health sciencesparasitic diseasesmedicineHumansTrypanosoma cruziMolecular Biologychagas diseaseBinding Sites010405 organic chemistryOrganic ChemistryPlasmodium falciparumbiology.organism_classificationmedicine.diseaseProtein Structure Tertiary0104 chemical sciences030104 developmental biologyEnzymeCysteineBioorganic & Medicinal Chemistry
researchProduct

New Thiazole Nortopsentin Analogues Inhibit Bacterial Biofilm Formation.

2018

New thiazole nortopsentin analogues were conveniently synthesized and evaluated for their activity as inhibitors of biofilm formation of relevant Gram-positive and Gram-negative pathogens. All compounds were able to interfere with the first step of biofilm formation in a dose-dependent manner, showing a selectivity against the staphylococcal strains. The most active derivatives elicited IC50 values against Staphylococcus aureus ATCC 25923, ranging from 0.40&ndash

0301 basic medicinethiazole derivativeAquatic OrganismsIndolesDrug ResistancePharmaceutical ScienceBacterial growthAntibiofilm agentmedicine.disease_cause01 natural scienceschemistry.chemical_compoundDrug Discoveryanti-virulence agents; antibiofilm agents; marine alkaloids; nortopsentin analogues; thiazole derivatives; Anti-Bacterial Agents; Aquatic Organisms; Biofilms; Humans; Imidazoles; Indoles; Inhibitory Concentration 50; Staphylococcal Infections; Staphylococcus aureus; Thiazoles; Drug Resistance; Bacterial; Anti-virulence agents; Antibiofilm agents; Marine alkaloids; Nortopsentin analogues; Thiazole derivativesPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5Aquatic OrganismBiofilmBacterialImidazolesantibiofilm agentsStaphylococcal InfectionsAnti-Bacterial Agentsnortopsentin analoguesBiochemistryStaphylococcus aureusStaphylococcus aureumarine alkaloidsthiazole derivativesSelectivityHumanStaphylococcus aureusAnti-virulence agentNortopsentin analogueArticle03 medical and health sciencesInhibitory Concentration 50Anti-Bacterial AgentDrug Resistance BacterialIc50 valuesmedicineHumansThiazoleImidazoleStaphylococcal Infection010405 organic chemistryBiofilmSettore CHIM/08 - Chimica Farmaceutica0104 chemical sciencesmarine alkaloidThiazoles030104 developmental biologychemistrylcsh:Biology (General)anti-virulence agentsIndoleBiofilmsThiazoleMarine drugs
researchProduct

The B-cell receptor in control of tumor B-cell fitness: Biology and clinical relevance

2019

Surface expression of a functional B cell antigen receptor (BCR) is essential for the survival and proliferation of mature B cells. Most types of B-cell lymphoproliferative disorders retain surface BCR expression, including B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). Targeting BCR effectors in B-NHL cell lines in vitro has indicated that this signaling axis is crucial for malignant B cell growth. This has led to the development of inhibitors of BCR signaling, which are currently used for the treatment of CLL and several B-NHL subtypes. Recent studies based on conditional BCR inactivation in a MYC-driven mouse B-cell lymphoma model have revisited the role of …

0301 basic medicinetumor cell fitnessChronic lymphocytic leukemiaImmunologyB-cell receptorPopulationReceptors Antigen B-CellLymphoproliferative disorderslymphomaBiologyMice03 medical and health sciences0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesB-cell receptorTumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyeducationHematologic NeoplasmB cellBCR inhibitorB-Lymphocyteseducation.field_of_studyAnimalB-Lymphocytebreakpoint cluster regionB-cell receptor; BCR inhibitors; c-MYC; lymphoma; lymphoma resistance; tumor cell fitnesslymphoma resistancemedicine.diseaseLymphoproliferative DisordersLymphomaBCR inhibitorsPhenotype030104 developmental biologymedicine.anatomical_structurec-MYCtumor cell fitneCell cultureLymphoproliferative DisorderHematologic NeoplasmsCancer researchHumanSignal Transduction030215 immunology
researchProduct

Novel activities of safe-in-human broad-spectrum antiviral agents

2018

According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley feve…

0301 basic medicineviruksetviruses030106 microbiologyAPPROVED DRUGSHEPATITIS-C VIRUSINFLUENZA-A VIRUSBioinformaticsAntiviral AgentsArticle03 medical and health sciencesBroad spectrumVirologyHumansRNA VirusesvirusesCELL-CULTUREPharmacologyZIKA VIRUS-INFECTIONviral diseasesECHOVIRUS 1ta1183DNA VirusesDrug Repositioningta1182MOUSE MODELLIVER-TRANSPLANTATION3. Good healthDrug repositioning030104 developmental biology317 PharmacyVirus DiseasesvirustauditENTRY3111 BiomedicineViral diseaseINHIBITORSAntiviral Research
researchProduct